Endocyte again changes terms of public offering
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
R&D
Articles
Potential competitor to Lilly drug shows promise in study
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
21st Century Fund pockets a payoff from sale
The state’s principal fund investing in high-tech companies has reached a milestone—for the first time recouping all the money it granted an emerging company, and then some.
Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Lilly partner moves up timetable for diabetes drug
Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.
Lilly, other big drugmakers shut out by FDA in 2010
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Indiana Seed Fund makes 11th investment
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
Lilly, Acrux receive FDA approval for Axiron
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
Study: Arthritis drug co-developed by Lilly shows promise
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Drugmaker restarts race to boost ‘good’ cholesterol
Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
Acquisition big step for Lilly Diagnostics
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
Lilly to open diabetes research center in China
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Eli Lilly will have to beat odds to meet drug-rollout goals
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
UPDATE: Lilly, others see stock slide after drug rejection
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
Consultants: Pharma industry facing huge changes
To date, most analysts say health reform turned out pretty well for the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen over the past three decades.
CEO says Lilly still not interested in huge acquisitions
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
Lilly wins ban of generic Strattera pending appeal
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
Lilly wins further delay in sales of Strattera copies
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.